Background--Matrix metalloproteinase (MMP)-2 deficiency makes humans and mice susceptible to inflammation. Here, we reveal an MMP-2-mediated mechanism that modulates the inflammatory response via secretory phospholipase A 2 (sPLA 2 ), a phospholipid hydrolase that releases fatty acids, including precursors of eicosanoids.
In Vivo Responses to Dietary Cholesterol, Fasting, and Fasting-Refeeding
The dietary regimens in these studies followed previously described protocols. 9 In the cholesterol supplementation studies, Mmp2 À/À or WT mice (aged 12 to 14 weeks) were fed chow supplemented with 0% or 0.15% cholesterol for 2.5 days, 6.5 days, or 4 weeks. In this study, the mice were not fasted before they were killed.
In the fasting and fasting-refeeding studies, mice (aged 10 to 22 weeks) were fasted for 16 hours and then killed, or they were fasted for 16 hours and next fed "high-carb" (TD.88122 mouse diet) for 4 hours and then killed.
In Vivo Pharmacological MMP Inhibition
Mice (20 weeks old) were gavaged with 120 lL of water (vehicle) or MMP inhibitor (doxycycline) regimens of 50 mg/ kg per day for 3 days, 50 mg/kg per day for 15 days, or 300 mg/kg per day for 5 days and then killed.
In Vivo Pharmacological sPLA 2 Inhibition
Mice (20 weeks old) were gavaged with soybean oil (vehicle) or sPLA 2 inhibitor varespladib (10 mg/kg per day) prepared in soybean oil for 2 days and then killed.
Recombinant Adenovirus Construct
Green fluorescent protein (GFP) or human MMP-2-encoding adenovirus was generated using the AdEasy system. The pOTB7 plasmid containing MMP2 was obtained from ATCC. The MMP2 gene was excised from the plasmid via XhoI and EcoRI digestion, followed by mung bean nuclease digestion to generate blunt ends. The gene was inserted into GFP tracer-containing adenoviral shuttle vector pAdTrack-CMV EcoRV site, and the orientation of the gene was confirmed through restriction endonuclease digestion. The generated pAdTack-CMV-MMP2 plasmid was linearized via PmeI digestion and cotransformed into E coli BJ5183 with adenoviral backbone plasmid; then, pAdEasy-1. pAdTack-CMV-MMP2 was integrated into pAdEasy-1 via homologous recombination. Recombinants were selected for kanamycin resistance, and recombination was confirmed with the use of restriction endonuclease analysis. Finally, the linearized recombinant plasmid (by PacI) was transfected into HEK293 cells to generate GFP-expressing adenovirus (AdGFP) or mature human MMP-2-encoding adenovirus (AdMMP-2).
qRT-PCR
Cells were lysed in TRIzol. Tissue was extracted by homogenizing 30-to 50-mg pieces of frozen tissue at 4°C in 1 mL of TRIzol reagent using the Bullet Blender (Next Advance Inc., NY, USA). RNA was isolated from TRIzol according to manufacturer's instructions,andcDNAwasgeneratedfromRNAbyusingrandom primers and Superscript II reverse transcriptase. Expression analysis of the reported genes was performed with TaqMan qRT-PCR by using the ABI 7900 HT sequence detection system (Applied Biosystems). Gapdh and Actb (to confirm interpretation ofdatarelativetoGapdh)wereusedasinternalstandards.TheRT-PCR data chosen for the figures are relative to Gapdh.
Protein Analysis
Total protein content in tissue homogenate was assessed by using Bio-Rad Protein Assay according to the manufacturer's instructions or SDS-PAGE followed by Coomassie blue staining.
For determination of PLA2G5 protein, plasma and recombinant PLA2G5 solutions were diluted with a 1:5 volume of SDS-PAGE loading buffer (15% SDS, 8 mol/L urea, 10% 2-mercaptoethanol, 25% glycerol, 0.2 mol/L Tris, pH 6.8), heated at 37°C for 20 minutes, and subjected to 10% Tricine-SDS-PAGE as previously described. 10 After electrophoresis, proteins from the gels were transferred to a nitrocellulose membrane by using the TE22 system (Hoefer). Membranes were visualized with the use of Ponceau S acid staining; scanned to assess protein load; blocked in 5% bovine serum albumin in 20 mmol/L Tris, 150 mmol/L NaCl, pH 7.4, containing 0.1% Tween-20; probed overnight with primary antibodies to PLA2G5; rinsed; probed for 30 minutes with secondary antibodies; and washed in 20 mmol/L Tris, 150 mmol/L NaCl, pH 7.4, containing 0.1% Tween-20 to remove excess of antibody. PLA2G5 immunoreactivity was then detected by using ECL detection reagent. MMP-2 activity was measured with gelatin zymography, by using SDS-PAGE gels embedded with 2 mg/mL gelatin. After electrophoresis, the gels were washed 3 times in 2.5% Triton X-100 for 20 minutes (to remove excess SDS) and then incubated for 16 hours at 37°C in a buffer of 5 mmol/L CaCl 2 , 150 mmol/L NaCl, 0.5 mmol/L NaN 3 , and 25 mmol/ L Tris, pH 7.4 (for activity development). Gels were stained with Coomassie brilliant blue to visualize bands with gelatinase activity.
Cytokine analysis was outsourced to Eve Technologies (Calgary, Canada) with use of the Mouse Cytokine Array/ Chemokine Array 31-Plex (Eve Technologies).
Measurements of Phospholipases and Eicosanoids
Except where indicated otherwise, secretory, cytosolic, and calcium-independent PLA 2 activities were measured by using the respective assay kits (Cayman), which use diheptanoyl thio-phosphatidylcholine (PC) or arachidonoyl thio-PC as substrates to distinguish sPLA 2 from cPLA 2 and iPLA 2 .
Prostaglandin (PG) E 2 in the heart, liver, and hypothalamus was measured by using the Prostaglandin E 2 Express EIA Kit (Cayman). Free 8-isoprostane concentrations in the plasma were measured by using the 8-isoprostane EIA Kit (Cayman).
To determine the molecular weight of the plasma and cardiac sPLA 2 activities, we subjected plasma or heart homogenates to a novel zymographic technique. Hearts were homogenized by using the Bullet Blender in 10 lL/mg sPLA 2 assay buffer (100 mmol/L KCl, 10 mmol/L CaCl 2 , 0.3 mmol/L Triton X-100, 25 mmol/L Tris-HCl, pH 7.4). Bromophenol blue and 20% glycerol were added to the samples for loading into a 10% SDS-PAGE or 10% T (grams of acrylamide and bisacrylamide per 100 ml of solution -in percent), 3% C (ratio of bisacrylamide to acrylamide and bisacrylamide) Tricine-SDS-PAGE gel. After electrophoresis, the gels were reverse-stained by using our previously developed zincimidazole reverse stain technique. 11 Lanes were then cut into equal-sized sections to cover the full range of molecular weights. The individual sections of gel were incubated for 5 minutes in 200 lL of 100 mmol/L EDTA (to mobilize proteins), washed once with water (to remove excess EDTA), and then washed (29 10 minutes) with 2.5% Triton X-100, 10 mmol/L CaCl 2 , 25 mmol/L Tris, pH 9.0 (to remove excess SDS). Next, 200 lL of sPLA 2 assay buffer was added to gel pieces, and the pieces were nebulized by using the Bullet Blender. Samples were centrifuged at 20 000g for 5 minutes, and activity in the eluates (supernatant) was measured by using the sPLA 2 assay kit.
Enzyme Inhibition Assays
Indoxam-inhibition concentration-response was constructed for 5 different concentrations by measuring the residual activity with use of the microtiter plate fluorescent assay of sPLA 2 s with pyrene-labeled phosphatidyl-glycerol as the substrate as described previously.
(30 or 100 lg/kg). To measure the effect of sPLA 2 inhibition on the fever response to LPS, we examined mice administered varespladib (10 mg/kg per day, orally for 2 days with the second dose immediately preceding the intraperitoneal injection of LPS). To measure the effect of MMP-2 overexpression on the fever response, we examined mice that were intraperitoneally injected with either AdMMP-2 or AdGFP (%10 8 pfu) and then injected 3 days later with LPS (100 lg/kg). 
Cell Culture Studies
For RNA interference studies, we used a stable cell line of Mmp2 deficiency created from fibroblasts isolated from WT, Mmp2 À/À , or Mmp9 À/À lungs. These cells were chosen for 4 key traits: (1) preserved ability to proliferate in culture without any detectable phenotypic changes after subsequent passages (up to at least 30 passages), (2) expression of PLA2G5, the major cardiac sPLA 2 , (3) expression of a proinflammatory phenotype, and (4) amenability to efficient transduction with siRNAs against PLA2G5. The cells used for this study were cultured in EMEM with 10% FBS, 100 U/mL penicillin, and 100 lg/mL streptomycin, at a density of %10 4 cells/cm 2 . Attached fibroblasts were transfected with siRNAs against PLA2G5 or scrambled RNA (control) over a period of 3 days by using Lipofectamine RNAiMAX according to the manufacturer's instructions.
Statistical Analysis
The main unit of statistical analysis for qRT-PCR and systolic blood pressure measurements was the animal. In qRT-PCR analyses, the RNA isolated for each mouse was measured in triplicate, and the resulting average value was used to compute the mean of said mRNA for each group. Similarly, the mean of the systolic blood pressure for each group was computed from the average of 8 to 10 individual measurements for each mouse in the group. For PLA 2 s, PGE 2 , and isoprostanes, the main unit of statistical analysis was the duplicate of pooled samples, as described in the corresponding figure legends. Unless otherwise indicated, the results are reported as meanAESEM values. Results were analyzed by using SigmaPlot 11 software (Systat Software). The specific statistical tests used are indicated in the corresponding figure legends. showed a %25% elevation of hepatic cPLA 2 and iPLA 2 activity and dramatically elevated plasma sPLA 2 activity ( Figure 1A ). The plasma sPLA 2 activity of Mmp2 À/À mice was found at a molecular weight range of 3 to 30 kDa through centrifugal filtration ( Figure 1B , left). Development of a novel combination of techniques, involving nonreducing SDS-PAGE followed by reverse-stain 11 and sPLA 2 activity assay, revealed that Mmp2 À/À plasma sPLA 2 has a molecular weight of %20 kDa ( Figure 1B , right). Plasma sPLA 2 activity was less elevated in Mmp7 À/À and Mmp9 À/À mice, indicating a predominant role of MMP-2 ( Figure 1A) . Notably, plasma sPLA 2 activity was also elevated in Mmp2 À/À mice subjected to diverse nutritional regimens including fasting-refeeding and excess cholesterol supplementation ( Figure 2A ). In these nutritional regimens, MMP-2 levels remained unchanged in WT mice ( Figure 2B ). These data consistently indicate that MMP-2 is a negative regulator of sPLA 2 activity. The sn-2 position of phospholipids is enriched in polyunsaturated fatty acids (eg, arachidonic acid), which is the precursor of all eicosanoids, including PGE 2 (which is synthesized downstream of cyclooxygenases) and 8-isoprostanes (which are formed independent of cyclooxygenases).
Results
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À/À mice, hepatic PGE 2 ( Figure 3A ) and plasma 8-isoprostanes ( Figure 3B ) were both increased. However, PGE 2 levels in Mmp7 À/À and Mmp9 À/À mice were not as elevated (Figure 3A) . Treatment of Mmp2 À/À mice with the sPLA 2 inhibitor varespladib normalized the levels of plasma sPLA 2 and hepatic PGE 2 ( Figure 3C ). These data showed that MMP-2 deficiency causes excess sPLA 2 activity, which, in turn, elevates PGE 2 . Mimicking Mmp2 deficiency, administration of the US Food and Drug Administration (FDA)-approved MMP inhibitor doxycycline to WT mice dose-dependently increased the activity of plasma sPLA 2 and the hepatic PGE 2 ( Figure 4A ). MMP-2 upregulation by transducing mice with human MMP-2-encoding adenovirus (AdMMP-2) decreased plasma sPLA 2 activity (versus AdGFP) in both WT ( Figures 4B and 5A ) and Mmp2 À/À mice ( Figures 4B and 5B ). This finding was consistent with MMP-2 being a negative regulator of sPLA 2 .
MMP-2 Is a Negative Regulator of Fever
At baseline, Mmp2 À/À mice exhibited signs of a proinflammatory state as indicated by the increased mRNA expression of the genes encoding tumor necrosis factor (TNF)-a (Tnf), interleukin (IL)-1b (Il1b), monocyte chemoattractant protein-1 (MCP-1) (Ccl2), regulated on activation, normal T cell expressed and secreted (RANTES) (Ccl5), and chemokine (C-C motif) ligand 6 (CCL6) (Ccl6) in the heart and liver and downregulated expression of liver X receptor-a (Nr1h3) ( Figure 6 elevated and that of Nr1h3 was not decreased ( Figure S1 and data not shown).
In response to bacterial LPS, PGE 2 synthesized by the PLA 2 /cyclooxygenase/PGE synthase pathway promotes fever and inflammation. 15 We administered LPS (30 lg/kg) to WT and Mmp2 À/À mice and searched for signs of inflammation, endoplasmic reticulum stress, or lipid metabolic dysregulation by using qRT-PCR and a cytokine array. Five hours after LPS administration, hepatic and cardiac mRNA expression of the genes encoding TNF-a (Tnf), IL-1b (Il1b), MCP-1 (Ccl2), RANTES (Ccl5), and CCL6 (Ccl6) was exacerbated in Transduction with AdMMP-2, which resulted in hepatic overexpression of human MMP-2, ameliorated LPS-induced fever and reduced PGE 2 levels in the brain ( Figure S4 ).
Therefore, in the absence of MMP-2, LPS-induced fever is signaled through a varespladib-inhibitable (ie, sPLA 2 -dependent) pathway, which would otherwise be inhibited by MMP-2. The inhibitory effect of MMP-2 in fever is obliterated when the LPS dose is sufficiently high. These data identify MMP-2 as a novel negative regulator of LPS-induced fever.
The Heart Is a Major Source of sPLA 2 Activity
We compared sPLA 2 activity in plasma, liver, heart, kidney, and skeletal muscle. Strikingly, the sPLA 2 activity in Mmp2 and WT hearts (259 and 308 lmol/L, respectively). These data indicated that the plasma and cardiac sPLA 2 enzymes were the same. The cardiac sPLA 2 depended on calcium for its activity ( Figure 10A ) and was active over a broad pH range with maximal activity at pH 7.5 ( Figure 10B ) and a molecular weight of %20 kDa ( Figure 10C ). In haploinsufficient (Mmp2 +/À ) mice, the levels of cardiac sPLA 2 activity were as approximately half those of Mmp2 À/À mice ( Figure 11A ). are not effectively inhibited by varespladib (which blunted sPLA 2 activity and PGE 2 levels in Mmp2 À/À mice [ Figure 3C ]).
(3) PLA2G2E could be excluded because it promotes obesity, 17 while MMP-2 deficiency protects against obesity. 18 (4) PLA2G2D could also be excluded because it ameliorates inflammation, 19 whereas MMP-2 deficiency results in a proinflammatory state (Figures 6 and 7) . (5) PLA2G12A is unlikely because this has very low PLA 2 activity.
qRT-PCR analysis of the entire sPLA 2 gene family expressed in C57BL/6 mice indicated that their expression was equal in WT and Mmp2 À/À hearts ( Figure 11B ).
Inhibition studies with the pan-sPLA 2 Therefore, cardiac sPLA 2 is either a mixture of sPLA 2 s or a completely novel (ie, a nonclassic) member of the sPLA 2 family. The mRNA for Pla2g5 is highly expressed in cardiac and vascular atherosclerotic tissue. 20 In the absence of PLA2G2A
(as in our mouse model), PLA2G5 might be a major contributor to the composite sPLA 2 activity that circulates in plasma 20 and could thus contribute to inflammation in
Mmp2 deficiency, at least as a minor component. Indeed, showing that PLA2G5 could contribute to exacerbated inflammation characteristic of Mmp2 deficiency, PLA2G5 expression knock-down with siRNA ( Figure 12A ) caused significant downregulation of inflammatory markers in Mmp2 À/À but not in WT cell cultures ( Figure 12B ).
Studies summarized in Figure 13 show that recombinant human MMP-2 did not cleave or inactivate recombinant human PLA2G5 or PLA2G10. Addition of recombinant human MMP-2 to plasma ex vivo also did not inhibit plasma sPLA 2 activity. To examine the possible involvement of plasma factors, like activators or inhibitors of sPLA 2 , in the elevation of sPLA 2 in Mmp2 deficiency, we further spiked plasma of WT or Mmp2 À/À mice with recombinant human PLA2G5 for 4 to 16 hours. We were unable to detect any loss of the plasma PLA2G5 immunoreactivity or enzymatic activity ( Figure 13A through 13C). Western immunoblotting and time-resolved fluorescence immunoassay revealed similar yet very small amounts of PLA2G5 in plasma and cardiac homogenates from WT and Mmp2 À/À mice; these data were in line with the notion that MMP-2 deficiency does not regulate sPLA 2 expression ( Figure 13C and 13D) . Overall, the data obtained by targeting PLA2G5 showed that MMP-2 does not cleave or inactivate sPLA 2 in plasma, suggesting that MMP-2 might regulate sPLA 2 activity in tissue. Addition of recombinant human MMP-2 to Mmp2 À/À heart homogenates had no effect on the activity or the molecular weight of cardiac sPLA 2 ( Figure 13E ). Therefore, we hypothesized that MMP-2 inhibits the release of active sPLA 2 from the heart and tested this through the ex vivo analysis of myocardial releasates ( Figure 14A ).
MMP-2 Is a Negative Regulator of the Release of Active sPLA 2 From the Myocardium
Freshly isolated specimens of Mmp2 À/À myocardium released dramatically more sPLA 2 activity ex vivo than did similar specimens isolated from WT mice ( Figure 14B ). This release of sPLA 2 activity from Mmp2 À/À hearts, as well as the expression of inflammatory markers, was reduced by adenovirus-mediated expression of human MMP-2 ( Figure 14C ). The secreted enzyme was equal in molecular weight ( Figure 14C ) to the sPLA 2 isolated from cardiac homogenates ( Figure 1B) , suggesting that the active sPLA 2 in the heart does not require proteolytic maturation for secretion to occur. MMP-2 haploinsufficiency caused a reduction in ex vivo myocardial sPLA 2 release ( Figure 14D ). In the presence of Brefeldin A, an inhibitor of the classic secretory pathway, the myocardial release of sPLA 2 was significantly blunted ( Figure 14D ).
The MMP-2 Inhibitor Doxycycline Replicates Aspects of the Phenotype of Mmp2 Deficiency
The experiment described in Figure 4A revealed that doxycycline administration can induce an MMP-2 deficiency phenotype in WT mice. To further characterize whether doxycycline-induces phenotypic transformation in the heart, we administered doxycycline (50 mg/kg per day for 2 weeks) to WT mice and correlated their plasma and cardiac sPLA 2 levels to cardiac inflammatory marker expression ( Figure 15A ). We used Mmp2 À/À mice to define whether doxycycline induction of sPLA 2 was due to MMP-2 inhibition ( Figure 15B ). We made 3 important observations.
(1) Doxycycline upregulated plasma and cardiac sPLA 2 activity only in Mmp2 +/+ mice, not in Mmp2 À/À mice. (2) The elevation of plasma sPLA 2 activity by doxycycline preceded that of cardiac sPLA 2 . (3) Induction of proinflammatory genes in the heart was detectable only after cardiac sPLA 2 activity was significantly elevated (as assessed by qRT-PCR analysis of Ccl2, Tnf, Il1b, Ccl6, and Cxcl10) ( Figure 15B) . Therefore, when MMP-2 is deficient, the heart is a major source of highly active sPLA 2 . Plasma sPLA 2 activity may result from a systemic contribution, including the heart. Development of cardiac inflammation may require prior induction of cardiac sPLA 2 activity.
Emerging Functions of the MMP-2/sPLA 2 Axis in Cardiovascular Regulation
Direct evidence of the proinflammatory potential of cardiac sPLA 2 Treatment of mice with varespladib decreased the otherwise elevated levels of PGE 2 ( Figure 16A) and Tnf, Il1b, Ccl2, Ccl5, Ccl6, and Ccl24 mRNA in the heart of Mmp2 À/À mice ( Figure 16B ).
To confirm that cardiac sPLA 2 is indeed sufficient to cause inflammation, we purified the active enzyme from Mmp2 À/À hearts by using a preparative zymographic technique and injected it into WT mice ( Figure 17A ). The purified enzyme, which had the same K M app as the heart homogenate and plasma sPLA 2 s, had the opposite effect to sPLA 2 inhibition with varespladib: it increased plasma sPLA 2 activity and caused cardiac inflammation in recipient WT mice ( Figure 17B and 17C) .
Role of the MMP-2/sPLA 2 axis in cardiac metabolic homeostasis
Metabolic and inflammatory processes intercept at the level of several transcription factors such as liver X receptor and sterol-regulatory binding proteins (encoded by Nr1h3 and Srebf, respectively). 21, 22 To determine whether the MMP-2/ sPLA 2 axis impacted cardiac lipid metabolic as well as proinflammatory gene expression, we conducted qRT-PCR analysis of these transcription factors in mice administered -/- Figure 9 . The heart is a major source of sPLA 2 activity. sPLA 2 activity in the heart, plasma, and liver against the sPLA 2 Figure 18A ).
The MMP-2/sPLA 2 /cyclooxygenase axis regulates blood pressure homeostasis
Cyclooxygenase-derived prostanoids are major regulators of systemic blood pressure in both normal physiology and pathophysiology, with some prostaglandins being vasoconstrictive (eg, thromboxane A 2 ), whereas others are vasodilatory (eg, PGE 2 and PGI 2 ). 23 Treatment with indomethacin (to inhibit cyclooxygenasedependent production of eicosanoids) or varespladib at a regimen that inhibited PGE 2 ( Figure 16A ) triggered acute hypertension selectively in Mmp2 À/À , but not in WT, mice ( Figure 18B ).
Discussion
We discovered MMP-2 to be a major negative regulator of systemic sPLA 2 , which, in Mmp2 deficiency, leads to massive levels of sPLA 2 activity in the myocardium and requires Ca ++ for activity. The sPLA 2 activity in Mmp2 À/À heart homogenate was measured in the presence of EGTA (to chelate calcium) or an excess of calcium. Pools of n=3 were measured in duplicate. Similar results were obtained in 3 separate experiments. B, Cardiac sPLA 2 has a broad pH optimum in the basic pH range. The sPLA 2 activity of Mmp2 À/À mouse heart homogenate (pool of n=3 mice) was measured at the indicated pH values in duplicate. Similar results were obtained in 3 separate experiments. C, Molecular weight of cardiac sPLA 2 activity. Strategy for analytical isolation of cardiac sPLA 2 . Hearts were excised and homogenized, cardiac proteins (from 1.5 mg tissue) were resolved by molecular weight (non-reducing SDS-PAGE). After reverse staining (for protein band visualization without loss of activity), protein was eluted from the gel and assessed for sPLA 2 activity (vertical bar diagram). MMP indicates matrix metalloproteinase; ND, not detected; sPLA 2 , secreted phospholipase A 2 ; WT, wild-type.
plasma. As a result, Mmp2-deficient mice exhibit dysregulation of inflammatory and lipid metabolic genes in the heart, exacerbated fever, and a compensatory reliance on eicosanoids for blood pressure homeostasis. We found the heart to be a major source of circulating sPLA 2 , which can be readily unmasked when MMP-2 deficiency is 
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Mmp2 heart homogenate caused by either pharmacological inhibition or gene knock-out.
To validate the conclusions of this research, we combined integrative physiology studies with biochemical analysis including the development of an approach for high-resolution 1-step isolation of bioactive sPLA 2 from complex biological sources such as heart homogenates and plasma. To demonstrate the unique relevance of MMP-2, we conducted parallel studies of Mmp2
, and haploinsufficient (Mmp2 +/À ) mice. To exclude that the observed regulation of systemic sPLA 2 was a mere compensatory result of chronic Mmp gene deficiency, we further examined mice treated with the FDA-approved broad-spectrum MMP inhibitor doxycycline. We show that this latter model replicates many traits of Mmp2 gene deficiency, yet doxycycline failed to elevate plasma and cardiac sPLA 2 in Mmp2 mice; this was in line with the qRT-PCR data for Pla2g5 (shown in Figure 11B ). E, MMP-2 does not cleave cardiac sPLA 2 . Lack of effect of incubation with recombinant human MMP-2 on the sPLA 2 from Mmp2 À/À heart homogenates (pool of n=3 hearts). Heart homogenate was redundant studies unambiguously demonstrated the existence of a novel heart-centric MMP-2/sPLA 2 signaling axis that modulates cardiac inflammation and metabolism, systemic blood pressure homeostasis, and fever. We have not yet discovered the mechanism by which MMP-2 inhibits sPLA 2 activation and systemic release. Although we have data pointing to inflammation being secondary to high sPLA 2 in Mmp2 deficiency, further studies are warranted to firmly establish whether preexisting inflammation in Mmp2-deficient mice can be causative of high sPLA 2 levels (Figure 19 ).
Phospholipase A 2 was discovered in the 19th century as a major active component in snake venom. The subsequent identification of sPLA 2 in mammalian systems began with pancreatic PLA2G1B and then PLA2G2A from human synovial fluid. Members of the family of secreted PLA 2 enzymes depend on calcium for activity and have 6 to 8 disulfide bridges and a histidine-aspartate dyad that catalyzes the hydrolysis of water, which enables a nucleophilic attack that releases fatty acids from the sn-2 position of membrane glycerophospholipids. 16 Secretory PLA 2 isoenzymes have a low molecular mass of %16 kDa. Despite catalyzing the same biochemical reaction, it is increasingly evident that sPLA 2 s play nonredundant, complex roles in inflammation and metabolism that depend on the target tissue and their relative affinity for specific cell membrane phospholipids; the latter being a function of the head group and the specific fatty acid in the sn-2 position. PLA2G2A, PLA2G5, and PLA2G10, which are considered to be the major contributors to plasma PLA 2 activity in humans, 20 have different induction profiles; for example, PLA2G5 is induced by a Western diet, whereas PLA2G2A is induced by proinflammatory stimuli (eg, bacterial LPS). 24 While PLA2G3
and PLA2G5 have the potential to promote atherogenesis,
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PLA2G10 may limit atherogenesis. 25 Like PLA2G5, PLA2G2E is diet inducible. In obesity, PLA2G2E and PLA2G5 are both upregulated in adipose tissue, where PLA2G2E alters lipoprotein phospholipids and facilitates lipid accumulation in adipose tissue and liver and PLA2G5 counteracts adipose tissue inflammation and hyperlipidemia. 17 Similarly, in the context of immune complex-induced arthritis, where PLA2G2A is a mediator, PLA2G5 may protect against inflammation by promoting immune complex clearance. 26 Our findings position the heart at the center of a paradigm where cardiac sPLA 2 acts in a hormonal fashion to affect inflammatory and metabolic gene expression, fever, and blood pressure homeostasis under negative regulation by MMP-2, and possibly other MMPs (as demonstrated by the lesser effects of MMP-7 and MMP-9). PLA2G5 is the major sPLA 2 expressed in the heart. Our siRNA studies conducted with PLA2G5-expressing Mmp2 +/+ and Mmp2 À/À cell cultures indicated that this sPLA 2 contributes to the quantitative trait of MMP-2 deficiency in a significant way. However, we cannot exclude that MMP regulation is a general mechanism controlling the release of multiple sPLA 2 isoforms (not just PLA2G5) from tissue. This notion is supported by our enzyme inhibition studies with indoxam. Further, when MMP-2 is inhibited with doxycycline, plasma sPLA 2 increases earlier than cardiac sPLA 2 activity, which ultimately precedes cardiac inflammation. Overall, the data point to MMP-2 being a major negative regulator for systemic release of active sPLA 2 from tissue. All human and mouse sPLA 2 s have an N-terminal signal peptide 16 and are, therefore, predicted to be secreted through the conventional endoplasmic reticulum-Golgi pathway. To date, little is known about how sPLA 2 secretion is regulated.
Nothing is known about how cardiac sPLA 2 activity affects the heart or the impact of the cardiac released sPLA 2 on systemic homeostasis. We have found that the release of sPLA 2 from myocardium occurs rapidly (reaching significance within 2 hours) and does not require stimulation. Myocardial sPLA 2 release was unmistakably elevated in Mmp2 À/À mice but inhibited in WT and in Mmp2 À/À mice forced to express human MMP-2. Confirming that MMP-2 negatively regulates sPLA 2 secretion in vivo, we found that plasma sPLA 2 is upregulated in Mmp2 À/À mice as well. Moreover, the K M app of the cardiac sPLA 2 was equal to that of the plasma sPLA 2 , indicating that the heart is a major source of systemic released sPLA 2 . Using a pharmacological inhibitor of MMP-2 and adenovirus-mediated overexpression of human MMP-2, we further showed that MMP-2-mediated proteolysis is necessary for suppressing the release of active sPLA 2 from tissue into the circulation and MMP-2 does not act via presecretion or postsecretion degradation of sPLA 2 or by regulating sPLA 2 transcription. Our data support the notion that sPLA 2 acts in a paracrine or endocrine fashion to alter the expression of inflammatory and lipogenic genes in target tissues, including the heart. Like sPLA 2 , MMP-2 is secreted into the circulation and may thereby affect sPLA 2 and the inflammatory and metabolic states in other tissues. This research suggests the intriguing possibility that the heart is involved in promotion of fever by way of being a major source of sPLA 2 . To date, sPLA 2 Preclinical studies indicated that pan-sPLA 2 inhibition with varespladib could reduce atherosclerotic lesions in rodents. 28 Varespladib effectively decreases total cholesterol, atherogenesis, and aneurysm formation in apolipoprotein E mouse models. 3 Early trials in humans yielded promising results for varespladib as a treatment in coronary heart disease. The PLASMA (Phospholipase Levels and Serological Markers of Atherosclerosis) and PLASMA II trials indicated that varespladib was effective at reducing the plasma concentrations of PLA2G2A, LDL cholesterol, and non-HDL cholesterol. 29, 30 Those studies provided the rationale and impetus for the VISTA-16 (Vascular Inflammation Suppression to Treat Acute 
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À/À mice (donor). Hearts were excised and homogenized, cardiac proteins (from 500 mg tissue) were resolved by nonreducing SDS-PAGE. After reverse staining, protein eluted from the gel was assessed for sPLA 2 activity, and the active fraction was filter-sterilized and injected into WT mice (recipient). An aliquot was used for enzyme kinetic analysis to confirm its identity (ie, same K M app ) as the sPLA 2 found in cardiac homogenates and plasma. B, sPLA 2 activity in the plasma and hearts of WT mice injected with cardiac sPLA 2 proinflammatory phenotype in WT mice reminiscent of Mmp2 deficiency. However, this cardiac proinflammatory phenotype was observed only in mice exhibiting sufficiently elevated cardiac sPLA 2 ( Figure 15 ). (3) Administration of cardiac sPLA 2 microisolated from Mmp2 À/À hearts triggered cardiac inflammation in recipient WT mice ( Figure 17 ). (4) LPS, which is a proinflammatory stimulus, did not acutely increase sPLA 2 activity in WT or Mmp2 À/À mice, at least within the time frame (ie, 5 hours) studied (Figures 6 through 8) . Further, addition of a proinflammatory cytokine regulated by MMP-2 cleavage (MCP-3) to Mmp2 +/+ and Mmp2 À/À fibroblast cultures for up to 48 hours did not elevate sPLA 2 activity (unpublished observations) (Evan Berry, BSc, and Carlos Fernandez-Patron, PhD, unpublished data, 2014). Therefore, the data point to MMP-2 acting as a negative regulator of the activation of a mixture of intracellular sPLA 2 s, which are proinflammatory, at least under the set of conditions studied. Once secreted from tissue, these sPLA 2 s may act in paracrine fashion. The interactions between MMP-2 and sPLA 2 likely form an autoregulatory loop. Indeed, previous research suggests that at least some sPLA 2 s (eg, PLAG1B) may stimulate pro-MMP-2 to MMP-2 activation through the PI3K/AKT pathway. 20 Negative regulation of the systemic release of sPLA 2 , a family of enzymes with complex protective and deleterious actions on inflammation and metabolic pathways, may further help to explain the complexity of MMP-2 (and MMP inhibitors) actions in the cardiovascular system and their dependence on the pathophysiological context.
In short, a heart-centric MMP-2/sPLA 2 axis may modulate blood pressure homeostasis, inflammatory and metabolic gene expression, and fever. Because MMP-2 is a target of doxycycline, this discovery may help better understand the spectrum of actions of this FDA-approved MMP inhibitor (and those of other MMP-2 inhibitors, as well). Suppression of sPLA 2 activity by MMP-2 is a general mechanism likely affecting many members of the sPLA 2 family; perhaps, including novel (ie, nonclassic) members of the sPLA 2 family, for which detection tools might need to be developed. Further studies will be required to validate the role of each sPLA 2 in inflammation and fever. Through the suppression of multiple sPLA 2 isoforms, MMP-2 could play as yet unsuspected roles in pain and in the pathogenesis of metabolic and inflammatory conditions such as arthritis, atherosclerosis, obesity, asthma, and anaphylaxis where MMP-2 and sPLA 2 are implicated, but their interaction remains unsuspected. 
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